Pharmacogenetically based dosing of thiopurines in childhood acute lymphoblastic leukemia: Influence on cure rates and risk of second cancer

Pediatric Blood and Cancer

Volumn 61, Issue 5, 2014, Pages 797-802

  Levinsen, Mette ^a   Rotevatn, Elisabeth Ørskov ^a   Rosthøj, Susanne ^b   Nersting, Jacob ^a   Abrahamsson, Jonas ^c   Appell, Malin Lindqvist ^d   Bergan, Stein ^e   Bechensteen, Anne Grete ^e   Harila Saari, Arja ^f   Heyman, Mats ^g   Jonsson, Olafur Gisli ^h   Maxild, Jakob Bernhard Cohn ^b   Niemi, Mikko ⁱ   Söderhäll, Stefan ^g   Schmiegelow, Kjeld ^a,j  

^a University of Copenhagen   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c Queen Sylvia's Children Hospital   (Sweden)

^d LINKÖPING UNIVERSITY   (Sweden)

^e OSLO UNIVERSITY HOSPITAL   (Norway)

^f OULU UNIVERSITY HOSPITAL   (Finland)

^g KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^h LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

ⁱ UNIVERSITY OF HELSINKI   (Finland)

^j UNIVERSITY OF COPENHAGEN   (Denmark)

more..

Author keywords

ALL; Late effects of cancer treatment; Outcomes research; Therapy

Indexed keywords

DEXAMETHASONE; FOLINIC ACID; MERCAPTOPURINE; METHOTREXATE; THIOPURINE METHYLTRANSFERASE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ARTICLE; CANCER RECURRENCE; CANCER RISK; CANCER THERAPY; CHILD; CHILDHOOD CANCER; CONTROLLED STUDY; FEMALE; HETEROZYGOSITY; HIGH RISK POPULATION; HUMAN; LEUKEMIA RELAPSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICAL SOCIETY; NORDIC SOCIETY OF PAEDIATRIC HAEMATOLOGY AND ONCOLOGY; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; SCHOOL CHILD; SECOND CANCER; TREATMENT DURATION;

ALL; LATE EFFECTS OF CANCER TREATMENT; OUTCOMES RESEARCH; THERAPY;

6-MERCAPTOPURINE; ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CYTOGENETIC ANALYSIS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; INFANT; MALE; METHOTREXATE; METHYLTRANSFERASES; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; RISK FACTORS;

EID: 84895756369     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24921     Document Type: Article

References (30)

1. Arico M, Baruchel A, Bertrand Y, et al. The seventh international childhood acute lymphoblastic leukemia workshop report: Palermo, Italy, January 29-30, 2005. Leukemia 2005; 19:1145-1152.
2. Davidsen ML, Dalhoff K, Schmiegelow K. Pharmacogenetics influence treatment efficacy in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol 2008; 30:831-849.
3. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing. Clin Pharmacol Ther 2011; 89:387-391.
4. Relling MV, Gardner EE, Sandborn WJ, et al. Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update. Clin Pharmacol Ther 2013; 93:324-325.
5. Karran P, Attard N. Thiopurines in current medical practice: Molecular mechanisms and contributions to therapy-related cancer. Nat Rev Cancer 2008; 8:24-36.
6. Lennard L, Welch JC, Lilleyman JS. Thiopurine drugs in the treatment of childhood leukaemia: The influence of inherited thiopurine methyltransferase activity on drug metabolism and cytotoxicity. Br J Clin Pharmacol 1997; 44:455-461.
7. Waters TR, Swann PF. Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine. Biochemistry 1997; 36:2501-2506.
8. Wang L, Weinshilboum R. Thiopurine S-methyltransferase pharmacogenetics: Insights, challenges and future directions. Oncogene 2006; 25:1629-1638.
9. Schmiegelow K, Forestier E, Kristinsson J, et al. Thiopurine methyltransferase activity is related to the risk of relapse of childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Leukemia 2009; 23:557-564.
10. Bo J, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: Relation to thiopurine metabolism. Cancer 1999; 86:1080-1086.
11. Schmiegelow K, Al-Modhwahi I, Andersen MK, et al. Methotrexate/6-mercaptopurine maintenance therapy influences the risk of a second malignant neoplasm after childhood acute lymphoblastic leukemia: Results from the NOPHO ALL-92 study. Blood 2009; 113:6077-6084.
12. Stanulla M, Schaeffeler E, Moricke A, et al. Thiopurine methyltransferase genetics is not a major risk factor for secondary malignant neoplasms after treatment of childhood acute lymphoblastic leukemia on Berlin-Frankfurt-Munster protocols. Blood 2009; 114:1314-1318.
13. Mitelman F. An international system for human cytogenetic nomenclature. Basel: S Karger; 1995.
14. Schmiegelow K, Forestier E, Hellebostad M, et al. Long-term results of NOPHO ALL-92 and ALL-2000 studies of childhood acute lymphoblastic leukemia. Leukemia 2010; 24:345-354.
15. Gustafsson G, Schmiegelow K, Forestier E, et al. Improving outcome through two decades in childhood ALL in the Nordic countries: The impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO). Leukemia 2000; 14:2267-2275.
16. Schmiegelow K, Bjork O, Glomstein A, et al. Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia. J Clin Oncol 2003; 21:1332-1339.
17. Schmiegelow K, Pulczynska MK. Maintenance chemotherapy for childhood acute lymphoblastic leukemia: Should dosage be guided by white blood cell counts? Am J Pediatr Hematol Oncol 1990; 12:462-467.
18. Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical models based on counting processes. New York: Springer Verlag; 1993.
19. Cox DR. Regression models and life-tables (with discussion). J R Stat Soc B 1972; 34:187-220.
20. Martinussen T, Scheike TH. Dynamic regression models for survival data. New York: Springer Verlag; 2006.
21. Lin DY, Wei LJ, Ying Z. Model-checking techniques based on cumulative residuals. Biometrics 2002; 58:1-12.
22. Cleveland WS, Grosse E, Shyu WM. Local regression models. In: Chambers JM, Hastie TJ, editors. Statistical models in S. Pacific Grove: Wadsworth & Brooks/Cole 1992.
23. Efron B. Nonparamtric estimates of standard error: The jackknife, the bootstrap and other methods. Biometrika 1981; 68:589-599.
24. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika 1986; 73:13-22.
25. Schmiegelow K, Levinsen MF, Attarbaschi A, et al. Second malignant neoplasms after treatment of childhood acute lymphoblastic leukemia. J Clin Oncol 2013; 31:2469-2476.
26. Relling MV, Yanishevski Y, Nemec J, et al. Etoposide and antimetabolite pharmacology in patients who develop secondary acute myeloid leukemia. Leukemia 1998; 12:346-352.
27. Relling MV, Rubnitz JE, Rivera GK, et al. High incidence of secondary brain tumours after radiotherapy and antimetabolites. Lancet 1999; 354:34-39.
28. Relling MV, Pui CH, Cheng C, et al. Thiopurine methyltransferase in acute lymphoblastic leukemia. Blood 2006; 107:843-844.
29. Olsen JH, Moller T, Anderson H, et al. Lifelong cancer incidence in 47, 697 patients treated for childhood cancer in the Nordic countries. J Natl Cancer Inst 2009; 101:806-813.
30. Richards S, Gray R, Peto R, et al. Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: Overview of 42 trials involving 12000 randomised children. Lancet 1996; 347:1783-1788.